
## Alice Panchaud

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/519753/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Antihistamine use during breastfeeding with focus on breast milk transfer and safety in humans: A systematic literature review. Basic and Clinical Pharmacology and Toxicology, 2022, 130, 171-181.	2.5	11
2	Use of Prescribed Drugs to Treat Chronic Diseases during Pregnancy in Outpatient Care in Switzerland between 2014 and 2018: Descriptive Analysis of Swiss Health Care Claims Data. International Journal of Environmental Research and Public Health, 2022, 19, 1456.	2.6	4
3	Self-Reported Medication Use among Pregnant and Breastfeeding Women during the COVID-19 Pandemic: A Cross-Sectional Study in Five European Countries. International Journal of Environmental Research and Public Health, 2022, 19, 1389.	2.6	16
4	Self-Reported Medication Use among Pregnant and Postpartum Women during the Third Wave of the COVID-19 Pandemic: A European Multinational Cross-Sectional Study. International Journal of Environmental Research and Public Health, 2022, 19, 5335.	2.6	14
5	Comment to "Pregnancy and COVID-19, focus on vaccine and pharmacological treatment― Journal of Reproductive Immunology, 2022, 152, 103639.	1.9	Ο
6	COVID-19 mRNA vaccine in pregnancy: Results of the Swiss COVI-PREG registry, an observational prospective cohort study. Lancet Regional Health - Europe, The, 2022, 18, 100410.	5.6	20
7	Protocol for a sequential, prospective meta-analysis to describe coronavirus disease 2019 (COVID-19) in the pregnancy and postpartum periods. PLoS ONE, 2022, 17, e0270150.	2.5	3
8	Recording of Chronic Diseases and Adverse Obstetric Outcomes during Hospitalizations for a Delivery in the National Swiss Hospital Medical Statistics Dataset between 2012 and 2018: An Observational Cross-Sectional Study. International Journal of Environmental Research and Public Health, 2022, 19, 7922.	2.6	0
9	Pregnancy outcome following first-trimester exposure to fingolimod: A collaborative ENTIS study. Multiple Sclerosis Journal, 2021, 27, 475-478.	3.0	16
10	Mental health status of pregnant and breastfeeding women during the COVIDâ€19 pandemic—A multinational crossâ€sectional study. Acta Obstetricia Et Gynecologica Scandinavica, 2021, 100, 1219-1229.	2.8	140
11	Valproate in pregnancy: authors' reply. Swiss Medical Weekly, 2021, 151, w20481.	1.6	Ο
12	Prolonged Maternal Zika Viremia as a Marker of Adverse Perinatal Outcomes. Emerging Infectious Diseases, 2021, 27, 490-498.	4.3	11
13	Maternal Infection and Adverse Pregnancy Outcomes among Pregnant Travellers: Results of the International Zika Virus in Pregnancy Registry. Viruses, 2021, 13, 341.	3.3	1
14	Vaccine Willingness and Impact of the COVID-19 Pandemic on Women's Perinatal Experiences and Practices—A Multinational, Cross-Sectional Study Covering the First Wave of the Pandemic. International Journal of Environmental Research and Public Health, 2021, 18, 3367.	2.6	83
15	Clinical and economic impacts of explicit tools detecting prescribing errors: A systematic review. Journal of Clinical Pharmacy and Therapeutics, 2021, 46, 877-886.	1.5	7
16	A comprehensive review on non-clinical methods to study transfer of medication into breast milk – A contribution from the ConcePTION project. Biomedicine and Pharmacotherapy, 2021, 136, 111038.	5.6	19
17	Exposure to alirocumab during the first trimester ofÂpregnancy: A case report. Birth Defects Research, 2021, 113, 1156-1160.	1.5	5
18	SARS-CoV-2 Vaccine Willingness among Pregnant and Breastfeeding Women during the First Pandemic Wave: A Cross-Sectional Study in Switzerland. Viruses, 2021, 13, 1199.	3.3	54

#	Article	IF	CITATIONS
19	Ability to detect potentially inappropriate prescribing in older patients: comparative analysis between PIM-Check and STOPP/STARTv2. European Journal of Clinical Pharmacology, 2021, 77, 1747-1756.	1.9	4
20	Association between confirmed congenital Zika infection at birth and outcomes up to 3 years of life. Nature Communications, 2021, 12, 3270.	12.8	21
21	Maternal outcomes and risk factors for COVID-19 severity among pregnant women. Scientific Reports, 2021, 11, 13898.	3.3	77
22	A review of the evidence on the risk of congenital malformations and neurodevelopmental disorders in association with antiseizure medications during pregnancy. Expert Opinion on Drug Safety, 2021, 20, 1-13.	2.4	5
23	Reply to Stroobandt, S.; Stroobandt, R. Data of the COVID-19 mRNA-Vaccine V-Safe Surveillance System and Pregnancy Registry Reveals Poor Embryonic and Second Trimester Fetal Survival Rate. Comment on "Stuckelberger et al. SARS-CoV-2 Vaccine Willingness among Pregnant and Breastfeeding Women during the First Pandemic Wave: A Cross-Sectional Study in Switzerland, Viruses 2021, 13, 1199â€.	3.3	3
24	Viruses, 2021, 13, 1546. Use of valproate in pregnancy and in women of childbearing age between 2014 and 2018 in Switzerland: a retrospective analysis of Swiss healthcare claims data. Swiss Medical Weekly, 2021, 151, w20386.	1.6	8
25	Impact of Pharmaceutical Interventions in Hospitalized Patients: A Comparative Study Between Clinical Pharmacists and an Explicit Criteria-Based Tool. Current Therapeutic Research, 2021, 95, 100650.	1.2	4
26	Use of drugs to treat symptoms and acute conditions during pregnancy in outpatient care in Switzerland between 2014 and 2018: analysis of Swiss healthcare claims data. Swiss Medical Weekly, 2021, 151, w30048.	1.6	11
27	Placental infection by Zika virus in French Guiana. Ultrasound in Obstetrics and Gynecology, 2020, 56, 740-748.	1.7	19
28	An international registry for emergent pathogens and pregnancy. Lancet, The, 2020, 395, 1483-1484.	13.7	32
29	Zika Virus. Pathogens, 2020, 9, 898.	2.8	54
30	Tachysystole and risk of cesarean section after labor induction using misoprostol: A cohort study. European Journal of Obstetrics, Gynecology and Reproductive Biology, 2020, 249, 54-58.	1.1	1
31	<scp>SARSâ€CoVâ€2</scp> in the context of past coronaviruses epidemics: Consideration for prenatal care. Prenatal Diagnosis, 2020, 40, 1641-1654.	2.3	22
32	Association Between Mode of Delivery Among Pregnant Women With COVID-19 and Maternal and Neonatal Outcomes in Spain. JAMA - Journal of the American Medical Association, 2020, 324, 296.	7.4	120
33	A population pharmacokinetic model for escitalopram and its major metabolite in depressive patients during the perinatal period: Prediction of infant drug exposure through breast milk. British Journal of Clinical Pharmacology, 2020, 86, 1642-1653.	2.4	13
34	Vertical transmission and materno-fetal outcomes in 13 patients with coronavirus disease 2019. Clinical Microbiology and Infection, 2020, 26, 1585-1587.	6.0	9
35	Should we stop aspirin prophylaxis in pregnant women diagnosed with COVIDâ€19?. Ultrasound in Obstetrics and Gynecology, 2020, 55, 843-844.	1.7	20
36	Beta-blocker use and up-titration after acute ST-segment elevation myocardial infarction: a cohort study. Swiss Medical Weekly, 2020, 150, w20321.	1.6	0

#	Article	IF	CITATIONS
37	Identifying pregnancies in insurance claims data: Methods and application to retinoid teratogenic surveillance. Pharmacoepidemiology and Drug Safety, 2019, 28, 1211-1221.	1.9	51
38	A critical analysis of the neurodevelopmental and neurosensory outcomes after 2 years for children with in utero Zika virus exposure. Nature Medicine, 2019, 25, 1641-1642.	30.7	8
39	Risk-benefit balance assessment of SSRI antidepressant use during pregnancy and lactation based on best available evidence – an update. Expert Opinion on Drug Safety, 2019, 18, 949-963.	2.4	47
40	Zika virus during pregnancy: From maternal exposure to congenital Zika virus syndrome. Prenatal Diagnosis, 2019, 39, 420-430.	2.3	54
41	Infant Exposure to Methylphenidate and Duloxetine During Lactation. Breastfeeding Medicine, 2018, 13, 221-225.	1.7	4
42	Pregnancy outcomes in women on metformin for diabetes or other indications among those seeking teratology information services. British Journal of Clinical Pharmacology, 2018, 84, 568-578.	2.4	35
43	Maternal-fetal transmission and adverse perinatal outcomes in pregnant women infected with Zika virus: prospective cohort study in French Guiana. BMJ: British Medical Journal, 2018, 363, k4431.	2.3	106
44	Self-reported perinatal depressive symptoms and postnatal symptom severity after treatment with antidepressants in pregnancy: a cross-sectional study across 12 European countries using the Edinburgh Postnatal Depression Scale. Clinical Epidemiology, 2018, Volume 10, 655-669.	3.0	20
45	Anticonvulsants and the risk of perinatal bleeding complications. Neurology, 2018, 91, e533-e542.	1.1	4
46	Zika virus, vaccines, and antiviral strategies. Expert Review of Anti-Infective Therapy, 2018, 16, 471-483.	4.4	19
47	Zika virus: are we going too far?. Lancet, The, 2017, 389, 151.	13.7	5
48	Simultaneous determination of selective serotonin reuptake inhibitors and their main metabolites in human breast milk by liquid chromatography-electrospray mass spectrometry. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2017, 1057, 101-109.	2.3	19
49	Pregabalin use early in pregnancy and the risk of major congenital malformations. Neurology, 2017, 88, 2020-2025.	1.1	56
50	Use of atypical antipsychotics in pregnancy and maternal gestational diabetes. Journal of Psychiatric Research, 2017, 95, 84-90.	3.1	24
51	Outbreak in meldonium positive laboratory tests: are we missing something?. British Journal of Sports Medicine, 2016, 50, 1422-1423.	6.7	4
52	Population pharmacokinetic analysis of elvitegravir and cobicistat in HIV-1-infected individuals. Journal of Antimicrobial Chemotherapy, 2016, 71, 1933-1942.	3.0	13
53	Pregnancy outcome following maternal exposure to pregabalin may call for concern. Neurology, 2016, 86, 2251-2257.	1.1	75
54	Clinical management of pregnant women exposed to Zika virus. Lancet Infectious Diseases, The, 2016, 16, 523.	9.1	35

#	Article	IF	CITATIONS
55	Stereoselective determination of citalopram and desmethylcitalopram in human plasma and breast milk by liquid chromatography tandem mass spectrometry. Journal of Pharmaceutical and Biomedical Analysis, 2016, 131, 233-245.	2.8	16
56	An international registry for women exposed to Zika virus during pregnancy: time for answers. Lancet Infectious Diseases, The, 2016, 16, 995-996.	9.1	12
57	Antipsychotic Use in Pregnancy and the Risk for Congenital Malformations. JAMA Psychiatry, 2016, 73, 938.	11.0	206
58	Harness shared data in international Zika registry. BMJ, The, 2016, 355, i5319.	6.0	3
59	Emerging Role of Zika Virus in Adverse Fetal and Neonatal Outcomes. Clinical Microbiology Reviews, 2016, 29, 659-694.	13.6	133
60	Clinical management of pregnant women exposed to Zika virus. Lancet Infectious Diseases, The, 2016, 16, 773.	9.1	12
61	Safety of Drugs during Pregnancy and Breastfeeding in Cystic Fibrosis Patients. Respiration, 2016, 91, 333-348.	2.6	11
62	Utility of an Algorithm to Increase the Accuracy of Medication History in an Obstetrical Setting. PLoS ONE, 2016, 11, e0151205.	2.5	1
63	Vitamin D Time Profile Based on the Contribution of Non-Genetic and Genetic Factors in HIV-Infected Individuals of European Ancestry. Antiviral Therapy, 2015, 20, 261-269.	1.0	5
64	Pregnancy Outcome Following Maternal Exposure to Mirtazapine. Journal of Clinical Psychopharmacology, 2015, 35, 250-259.	1.4	32
65	Risk-benefit balance assessment of SSRI antidepressant use during pregnancy and lactation based on best available evidence. Expert Opinion on Drug Safety, 2015, 14, 413-427.	2.4	47
66	PATTERNS AND FACTORS ASSOCIATED WITH LOW ADHERENCE TO PSYCHOTROPIC MEDICATIONS DURING PREGNANCY-A CROSS-SECTIONAL, MULTINATIONAL WEB-BASED STUDY. Depression and Anxiety, 2015, 32, 426-436.	4.1	47
67	Pregnancy outcome following maternal exposure to pregabalin: a reason for concern? a collaborative entis and motherisk study. Clinical Therapeutics, 2015, 37, e1.	2.5	0
68	Medication use in pregnancy: a cross-sectional, multinational web-based study. BMJ Open, 2014, 4, e004365.	1.9	311
69	Population pharmacokinetic modelling and evaluation of different dosage regimens for darunavir and ritonavir in HIV-infected individuals. Journal of Antimicrobial Chemotherapy, 2014, 69, 2489-2498.	3.0	31
70	Risk perception by healthcare professionals related to drug use during pregnancy: a Swiss survey. Swiss Medical Weekly, 2014, 144, w13936.	1.6	20
71	Pregnancy outcome following maternal exposure to statins: a multicentre prospective study. BJOG: an International Journal of Obstetrics and Gynaecology, 2013, 120, 463-471.	2.3	94
72	Authors' response to: Statins in pregnancy: safety and perspectives of therapeutic applications. BJOC: an International Journal of Obstetrics and Gynaecology, 2013, 120, 1440-1440.	2.3	1

#	Article	IF	CITATIONS
73	Pregnancy Outcomes Following Use of Escitalopram: A Prospective Comparative Cohort Study. Journal of Clinical Pharmacology, 2012, 52, 766-770.	2.0	48
74	Management of Deficient Lactation in Switzerland and Canada: A Survey of Midwives' Current Practices. Breastfeeding Medicine, 2012, 7, 317-318.	1.7	15
75	Pregnancy Outcome Following Exposure to Topical Retinoids: A Multicenter Prospective Study. Journal of Clinical Pharmacology, 2012, 52, 1844-1851.	2.0	48
76	Rates of Major Malformations in Infants Following Exposure to Duloxetine During Pregnancy. Journal of Clinical Psychiatry, 2012, 73, 1471.	2.2	27
77	Prediction of Infant Drug Exposure Through Breastfeeding: Population PK Modeling and Simulation of Fluoxetine Exposure. Clinical Pharmacology and Therapeutics, 2011, 89, 830-836.	4.7	24
78	Is use of nifurtimox for the treatment of Chagas disease compatible with breast feeding? A population pharmacokinetics analysis. Archives of Disease in Childhood, 2010, 95, 224-228.	1.9	36
79	Evaluation of the Risk of Congenital Cardiovascular Defects Associated With Use of Paroxetine During Pregnancy. American Journal of Psychiatry, 2008, 165, 749-752.	7.2	164
80	Place desÂapports oraux enÂacides gras oméga-3 dans laÂmucoviscidose. Nutrition Clinique Et Metabolisme, 2006, 20, 41-47.	0.5	0
81	Biological effects of a dietary omega-3 polyunsaturated fatty acids supplementation in cystic fibrosis patients: A randomized, crossover placebo-controlled trial. Clinical Nutrition, 2006, 25, 418-427.	5.0	72
82	A validated liquid chromatography–mass spectrometry method for the determination of leukotrienes B4 and B5 produced by stimulated human polymorphonuclear leukocytes. Analytical Biochemistry, 2005, 341, 58-68.	2.4	10